Original Article

Synthesis of Three Rimantadine Schiff Bases and Their Biological Effects on Serum Albumin

Bing-Mi Liu^a, Ping Ma^b, Xin Wang^a, Yu-Mei Kong^a, Li-Ping Zhang^a and Bin Liu^a*

^aCollege of Pharmacy, Liaoning University, Shenyang 110036, P. R. China. ^bDepartment of Clinical Pharmacology, General Hospital of the Rocket Force, Beijing 100088, P.R.China.

Abstract

Three new rimantadine Schiff bases (RSBs) were prepared, and then the interaction of RSBs with bovine serum albumin (BSA) was investigated using fluorescence, synchronous fluorescence, UV-vis absorption spectroscopy under physiological conditions. The results showed that the three RSBs effectively quenched the intrinsic fluorescence of BSA via static quenching. Binding constant (K_a), number of binding sites (n), and the binding distance (r) between three RSBs and BSA were calculated by Stern-Volmer equation and Förster's theory in this study. According to the results of displacement experiments of site probes, it was considered that the binding sites were located in hydrophobic cavities in sub-domains IIA of BSA. What is more, synchronous fluorescence studies indicated that the hydrophobicity around tryptophan residues was increased with the addition of rimantadine-o-vanillin (ROV) and rimantadine-4-methoxy-salicylaldehyde (RS).

Keywords: Rimantadine schiff base (RSB); Bovine serum albumin (BSA); Interaction; Fluorescence.

Introduction

Schiff bases are a category of compounds containing C=N group. It is reported that many Schiff bases show a variety of interesting biological actions, including antibacterial, antifungal, anticancer and antiviral actions (1, 2). So, in recent years, some researches have been concentrated on them (3-5).

Rimantadine hydrochloride (α -methyl-1-adamantane methylamine hydrochloride), which exhibits equal efficacy and fewer adverse reactions than amantadine hydrochloride, has been clinically used for therapy of infections caused by a broad range of RNA-containing viruses, in particular the influenza A virus (6,7). It has also been reported that rimantadine hydrochloride has some effects on Parkinson's disease. Salicylaldehyde and its derivatives are a kind of important chemical-industrial raw material and organic synthesis midbody (8). Also, they are often used in medicine chemical engineering (9) because of their biological activities, such as anti-inflammatory, antibacterial and antiviral activities (10, 11).

In recent years, the new pattern influenzal characteristic is often amphibianous. That is, the influenza is caused by viruses and germs at the same time (12, 13). Therefore, it is necessary to design the difunctional drugs, which have antiviral and antibacterial actions simultaneously (14). In this work, three new rimantadine Schiff bases (RSBs), rimantadine-salicylaldehyde

^{*} Corresponding author:

E-mail: liubinzehao@163.com (B. Liu)



Figure 1. Molecular structures of rimantadine-salicylaldehyde (RS), rimantadine-o-vanillin (ROV) and rimantadine-4-methoxy-salicylaldehyde (RMS) Schiff bases.

(RS), rimantadine-o-vanillin (ROV) and rimantadine-4-methoxy-salicylaldehyde (RMS), were synthesized which would display the better biologic activities. The molecular structures of three RSBs are shown in Figure 1.

Protein plays an important role in life processes. Serum albumins are the most abundant proteins in the plasma and have many physiological functions, the most outstanding property of which is their ability to bind reversibly a large variety of ligands, such as cystein, glutathione, Schiff base ligands (15, 16) and so on. The binding ability of drug-albumin in blood stream may have a significant impact on distribution, free concentration, and metabolism of drug. Thus, it is important and necessary to study the interaction of drug with serum albumins at molecular level.

Spectroscopic method has been widely applied in investigating drug binding with albumin because of its accuracy, sensitivity, rapidity and convenience of usage (17). Hence, in this study, the interaction of RSBs (RS, ROV, RMS) with BSA was investigated via UVvis absorption and fluorescence spectroscopy. Besides, the binding sites of RSBs to BSA molecules were also explored by site probes (ketoprofen and ibuprofen) (18).

Experimental

Rimantadine hydrochloride was obtained from Jinan Dachpharm Development Co., *Ltd.*, China.

Salicylaldehyde was purchased from Sinopharm Chemical Reagent Co., *Ltd.*, China. The o-vanillin and 4- methoxy-salicylaldehyde were obtained from Tianjing Tianhe Chemical Reagent Co., *Ltd.* Bovine serum albumin (BSA, purity > 99.0 %) was purchased from Beijing Abxing Biological Technology Company. The BSA solution of 2.00 × 10⁻⁵ mol/L was prepared by dissolving 1.340 g BSA in 1 L buffer and kept in the dark at 4 °C. Buffer (pH 7.4) consisted of Tris (0.2 mol/L) and HCl (0.1 mol/L), and the ion strength was maintained by adding 0.05 mol/L NaCl. All other chemicals were of analytical reagent grade.

The structures of RSBs were analysed by an AV-600 NMR instrument (Bruker, Germany) and a Fourier transform infrared spectrophotometer (Spectrum 100, PerkinElmer Company, USA). Fluorescence emission spectra and synchronous spectra were collected on an F-7000 spetrofluorophotometer (Hitachi, Japan). The absorption spectra were recorded on a Cary 50 UV-vis spectrophotometer (Varian, USA).

Syntheses of rimantadine-salicylaldehyde (RS), rimantadine-o-vanillin (ROV) and rimantadine- 4-methoxy-salicylaldehyde (RMS)

4.747 g(0.022 mol) rimantadine hydrochloride and 1.234 g (0.022 mol) KOH were added to 50 mL ethanol and then stirred for 2 h at room temperature. The precipitate was filtered off, and then the solution was transferred to a flask. To this solution, 10 mL salicylaldehyde-ethanol solution (containing 0.02 mol salicylaldehyde)

je i							
System	Colour	Melting Point (°C)	ν(N - H) (cm ⁻¹)	v (C=O) (cm ⁻¹)	v (C=N) (cm ⁻¹)		
Rimantadine			2902				
Salicylaldehyde				1663			
RS	yellow	88-89			1630		
o-Vanillin				1639			
ROV	yellow	86-88			1628		
4-Methoxy- Salicylaldehyde				1659			
RMS	pale yellow	103-104			1622		

Table 1. Physical and Infrared spectral data of RS, ROV and RMS.

was added drop-wise and stirred at 80 °C for 2 h. After 2 h the reaction mixture was concentrated until RS (yellow precipitate) appeared on the bottom. Naturally cooling to room temperature, the solid mass formed was filtered and washed with ethanol three times and dried at 60 °C.

According to the method above, ROV and RMS were also synthesized. The related data as follows:

RS, m.p. 88–89 °C; 1H NMR (CDCl₃) δ : 1.18 (d, 3H, CH₃), 1.56 (s, 6H, CH₂), 1.67 (dd, J = 12.0, 42.6 Hz, 6H, CH₂), 1.99 (s, 3H, CH), 2.83 (q, 1H, N-CH), 6.86 (t, J = 7.8 Hz, 1H, Ph), 6.95 (d, J = 8.4 Hz, 1H, Ph), 7.24 (dd, J = 1.2, 7.2 Hz, 1H, Ph), 7.30 (m, 1H, Ph), 8.26 (s, 1H, CH=N), 13.91 (s,1H, Ar-OH).

ROV, m.p. 86–88 °C; 1H NMR (CDCl₃) δ : 1.18 (d, 3H, CH₃), 1.56 (s, 6H, CH₂), 1.66 (dd, J = 12.0, 41.4 Hz, 6H, CH₂), 1.97 (s, 3H, CH), 2.87 (q, 1H, N-CH), 3.90 (s, 3H, OCH₃), 6.76 (t, J = 7.8 Hz, 1H, Ph), 6.86 (dd, J = 1.2, 7.2 Hz, 1H, Ph), 6.90 (dd, J = 1.2, 7.8 Hz, 1H, Ph), 8.23 (s, 1H, CH=N), 14.59 (s,1H, Ar-OH).

RMS, m.p. 103–104 °C; 1H NMR (CDCl₃) δ : 1.19 (d, 3H, CH₃), 1.55(s, 6H, CH₂), 1.67 (dd, J = 12.0, 42.6 Hz, 6H, CH₂), 1.99 (s, 3H, CH), 2.84 (q, 1H, N-CH), 3.80 (s, 3H, OCH₃), 6.33 (dd, J = 2.4, 8.4 Hz, 1H, Ph), 6.38 (d, J = 3.0 Hz, 1H, Ph), 7.06 (d, J = 8.4 Hz, 1H, Ph), 8.02 (s, 1H, CH=N), 14.40 (s,1H, Ar-OH).

At the same time, their infrared spectra were also determined by using a Fourier transform infrared spectrophotometer. The corresponding results were offered in Table 1.

Spectroscopic measurements

The absorption spectra of the three RSBs were collected. At the same time, the fluorescence

spectra of BSA with and without RSBs were performed at 290 K in the range of 200-500 nm upon excitation at 280 nm. The widths of both the entrance and exit slit were set to 5 nm. The concentration of BSA firstly was fixed at 1.00 \times 10⁻⁵ mol/L, and then titrated with different amount of RSBs' stock solution (2.50 \times 10⁻³ mol/L), which was prepared by dissolving the appropriate amount of RSBs with alcohol, and then diluting with Tris-HCl-NaCl buffer in 100 mL volumetric flask.

For every addition, the mixture solution must be shaken and allowed to stand for 10 min. The synchronous fluorescence spectra were recorded from 200 to 500 nm at $\Delta \lambda = 15$ and $\Delta \lambda = 60$ nm, respectively. Appropriate blanks corresponding to the buffer were subtracted to correct the fluorescence or absorption background.

Results and Discussion

Infrared spectra of RS, ROV and RMS

Some physical data of three new RSBs and the most important IR peaks of the ligand are reported in Table 1. It can be seen that the v(C=O) of salicylaldehyde at 1663 cm⁻¹ disappears and the v(N-H) at 2902 cm⁻¹ of rimantadine also disappears, then a new peak appears at 1630 cm⁻¹, which could be attributed to C=N vibrations and support the formation of the RS. Similarly, new peaks observed at 1628 cm⁻¹ for ROV and at 1622 cm⁻¹ for RMS indicate the formation of the C=N bond.

Fluorescence spectra of BSA solutions with RS, ROV and RMS

Figure 2 shows the emission spectra of BSA



Figure 2. Fluorescence quenching spectra of BSA in the presence of RSBs (RS, ROV, RMS). ([RSBs]($a \rightarrow f$) = 0.00, 0.50, 1.00, 1.50, 2.00, 2.50 10⁻⁵ mol/L, [BSA] = 1.00 × 10⁻⁵ mol/L).

in the absence and presence of RSBs (RS, ROV, RMS). As can be seen from Figure 2, BSA had strong fluorescence emission with a peak at 340 nm on excitation at 280 nm. Furthermore, the addition of RSBs led to a concentration-BSA dependent quenching of intrinsic fluorescence intensity and the maximum emission wavelengths were slightly shifted from 340 nm to 337 nm for RS and ROV, 340 nm to 336 nm for RMS. These results indicate that the binding of RSBs to BSA occurs and the microenvironment around chromophore of BSA is changed upon addition of RSBs (RS, ROV, RMS).

To interpret the data from fluorescence quenching studies, it is important to understand what kinds of interaction take place between the fluorophore (BSA) and the quencher (RSBs). If it is assumed that the fluorescence quenching of BSA induced by RSBs are dynamic quenching process, fluorescence quenching is described by the Stern-Volmer equation:

$$F_{0}/F = 1 + K_{a}\tau_{0}[Q] = 1 + K_{SV}[Q]$$
 Equation (1)

The F_0 and F are the fluorescence intensities in the absence and presence of quencher, respectively. K_q is the quenching rate constant, τ_0 the average lifetime of the biomolecule in the absence of quencher, [Q] the concentration of RSBs, and $K_{SV} = K_q \tau_0$ is the Stern-Volmer quenching constant. The fluorescence lifetime of biopolymer is about 10⁻⁸ s (19).

The Stern-Volmer plots for the interaction of the three RSBs with BSA were shown in Figure 3(a), based on the measured fluorescence data and the corresponding K_{SV} , K_q values were calculated (Table 2). Obviously, the rate constants of BSA quenching procedure initiated

by RSBs (RS, ROV, RMS) are much greater than the maximum scatter collision quenching constant of the biomolecule ($K_q = 2.0 \times 10^{10}$ L/ mol·s). This means that the possible fluorescence quenching mechanism of BSA by RSBs is not initiated by dynamic collision but potentially from static quenching.

Binding constants and binding sites

Fluorescence intensity data can also be used to obtain the binding constant (K_a) and the binding site numbers (n). Equilibrium between free and bound molecules is given by equation (2) providing that small molecules bind independently to a set of equivalent sites on a macromolecule:

$$\log (F_a - F)/F = \log K_a + n \log [Q]$$
 Equation (2)

According to the above equation, the double logarithm plots were obtained (Figure 3(b)). K_a and *n* values were calculated and listed in Table 3. The correlation coefficients are all larger than 0.99 indicating that the interaction between RSBs and BSA agrees well with the site-binding model underlined in the above equation. As can be seen in Table 3, the values of K_a are larger than 10⁴, which indicate that there is a strong interaction between the three RSBs and BSA. The order is K_a (BSA + RMS) > K_a (BSA + RS) > K_a (BSA + ROV). The values of *n* are all approximately equal to 1, indicating that there is one class of binding site for the three RSBs towards BSA.

The binding distance between RSBs (RS, ROV, RMS) and BSA

According to the Förster's theory, the efficiency of energy transfer, *E*, is given by:



Figure 3. Stern-Volmer plots (a) and Double logarithm plots (b) for the interaction of RSBs with BSA ([RSBs] = 0.00, 0.50, 1.00, 1.50, 2.00, 2.50 × 10⁻⁵ mol/L, [BSA] = 1.00×10^{-5} mol/L, T = 290 K).

Table 2 Dynamic quenching constants (K_{SV}) and quenching rate constants (K_q) of RSBs+BSA solutions ([BSA] = 1.00 × 10⁻⁵ mol/L, T = 290 K).

	$K_{_{ m SV}}(imes 10^4 \ { m L/mol})$	$K_q (\times 10^{12} L/mol \cdot s)$	\mathbf{R}^2
BSA+RS	3.883	3.883	0.9956
BSA+ROV	4.648	4.648	0.9980
BSA+RMS	5.709	5.709	0.9880

$$E = 1 - F/F_0 = 1/[1 + (r/R_0)^6]$$
 Equation (3)

The F_0 and F are the fluorescence intensities of BSA solutions with 1.00×10^{-5} mol/L at 340 nm in the absence and presence of RSBs (RS, ROV, RMS) with 1.00×10^{-5} mol/L, respectively. The *r* is the donor-acceptor distance and R_0 is the distance at 50 % transfer efficiency. The value of R_0^{-6} can be calculated using the equation (4):

$$R_0^{6} = 8.8 \times 10^{-25} (K^2 n^{-4} \varphi_D J)$$
 Equation (4)

Where the K^2 is the spatial orientation factor of the dipole, *n* is the refractive index of medium, φ_D is the quantum yield of the donor in the absence of acceptor and *J* is the overlap integral of the emission spectrum of the donor (BSA) and the absorption spectrum of the acceptor (RSBs). In the present case, K^2 , *n* and φ_D are 2/3, 1.336 and 0.15 for BSA (20), respectively. And then, the *J* can be calculated by the equation:

$$J = \Sigma F(\lambda) \varepsilon(\lambda) \lambda^4 \Delta / \Sigma F(\lambda) \Delta \lambda \qquad \text{Equation (5)}$$

Where $F(\lambda)$ is the fluorescence intensity of the donor in the wavelength range λ to λ + $\Delta\lambda$ and $\varepsilon(\lambda)$ is the absorption coefficient of the acceptor at λ . Figure 4 shows the spectral overlap of fluorescence emission of BSA solution and UV-vis absorption of the three RSBs solutions, respectively. From these relationships, J, E, R_{a} and r of the three RSBs + BSA solutions can be calculated and the corresponding results were given in Table 4. Apparently, the donoracceptor distances are all less than 7.0 nm, which indicates that the energy transfer from BSA to RSBs (RS, ROV, RMS) occurs with high possibility. It also suggested that the bindings of these three RSBs to BSA molecules were formed through energy transfer, which

Table 3. Apparent binding constants (K_a) and binding sites (n) of the interaction of RSBs with BSA.

	$K_a (\times 10^4 L/mol)$	n	R ²
BSA+RS	3.251	0.9848	0.9954
BSA+ROV	2.749	0.9523	0.9976
BSA+RMS	16.029	1.0968	0.9932



Figure 4. Spectral overlap of fluorescence ($\lambda_{ex} = 280 \text{ nm}$) of BSA solution and absorption of RSBs (RS, ROV, RMS) solutions ([BSA] = [RSBs] = 1.00 × 10⁻⁵ mol/L).

Table 4 Corresponding results according to Föster's non-radioactive energy transfer theory ($[BSA] = [RSBs] = 1.00 \times 10^{-5} \text{ mol/L}$).

	E (%)	R ₀ (nm)	J (cm ³ ·L/mol)	r (nm)
BSA+RS	27.28	2.2004	4.1087×10 ⁻¹⁵	2.5909
BSA+ROV	31.82	2.2269	4.4152×10-15	2.5286
BSA+RMS	32.64	2.2289	4.4391×10 ⁻¹⁵	2.5150

quenched the fluorescence of BSA molecules.

The displacement experiments of site probes

BSA is composed of a single chain of 582 amino acid residues and can be divided into three homologous domains. And each domain can be subdivided into two sub-domains (A and B). Sudlow et al. have suggested two main distinct binding sites on BSA, site I and site II, which locate in the hydrophobic cavities of sub-domains IIA and IIIA, respectively (21). Many ligands, such as warfarin and ketoprofen, were found to bind preferentially to site I of BSA, while ibuprofen and chlorphenamine maleate showed affinity for site II (22). In order to identify the location of the RSBs binding site on BSA, the displacement experiments were carried out using the site probes ketoprofen and ibuprofen. The ratio of RSBs to BSA was kept at 5:1 in order to keep non-specific binding of probes to a minimum. The percentage of fluorescence probe displaced by the site probes was determined by measuring the changes in

fluorescence intensity according to the method proposed by Sudlow *et al.* (19):

$$F_2/F_1 \times 100 \%$$
 Equation (6)

The F_1 and F_2 denote the fluorescence of the RSBs + BSA solutions without and with the probe, respectively. The plots of F_2/F_1 against [probe]/[BSA] were shown in Figure 5. It can be seen that the fluorescence intensities were all remarkably affected by adding ketoprofen, while the changes were not significant with the addition of ibuprofen. These results indicated that ketoprofen displaced RSBs from the binding site while ibuprofen had a little effect on the binding of RSBs to BSA. Hence, we can conclude that site I is the main location for the three RSBs binding to BSA.

Synchronous fluorescence spectra

Synchronous fluorescence measurements provide information about the molecular



Figure 5. Effect of site probes on the fluorescence of RSBs+BSA solutions ([BSA] = $1.00 \times 10^{-5} \text{ mol/L}$, [RSBs] = $5.00 \times 10^{-5} \text{ mol/L}$, $\lambda_{ex} = 280 \text{ nm}$, $\lambda_{em} = 336 \text{ nm}$).



Figure 6. Synchronous fluorescence quenching spectra of BSA in the presence of RSBs (RS, ROV, RMS). ([RSBs] ($a \rightarrow f$) = 0.00, 0.50, 1.00, 1.50, 2.00, 2.50 × 10⁻⁵ mol/L; [BSA] = 1.00 × 10⁻⁵ mol/L).

microenvironment in the vicinity of the fluorophore functional groups. The maximum emission wavelengths of the residues are related to the polarity of the surrounding environment. Synchronous fluorescence spectra were obtained by simultaneously scanning excitation and emission monochromators. If $\Delta \lambda = 15$ nm, the synchronous fluorescence spectrum exhibits the spectral character only of tyrosine residues, and if $\Delta \lambda = 60$ nm, it exhibits that only of tryptophan residues. Synchronous fluorescence spectra of BSA upon addition of RSBs (RS, ROV, RMS) gained at $\Delta \lambda = 15$ and 60 nm were shown in Figure 6.

As shown in Figure 6, the quenching of the fluorescence intensity of all the three tryptophan residues are stronger than that of tyrosine residues, suggesting that tryptophan residues contribute greatly to the quenching of intrinsic fluorescence of BSA. Moreover, there was a slight blue shift of maximum emission wavelength of tryptophan residues with the addition of ROV or RMS, whereas no significant shift was observed with the addition of RS. It was likely due to that the polarities around tryptophan residues were decreased, the hydrophobicity was increased and the amino acid residues were less exposed to the solvent with the addition of ROV or RMS. It also can be seen that the tyrosine residues emission maximum kept unchanged, suggesting that the polarity around tryptophan residues had no remarkable change during the binding process. This indicates that the methoxy (OCH₃) group can change the interaction model of RSBs with BSA molecules.

Conclusion

Three new RSBs (RS, ROV and RMS) were successfully synthesized. Interactions between these three RSBs with BSA molecules were investigated and the experimental results indicated that these three RSBs can interact with BSA strongly in sub-domain IIA mainly through the hydrophobic interaction, which change the conformation of BSA. The binding degree of these three RSBs with BSA molecules ranks in the order of RS < ROV < RMS. The protein fluorescence quenching mechanism was mainly a static quenching process and the methoxy groups on the aromatic ring of drug molecules played an important role during the binding processes. This study is expected to provide important insight into the interactions of serum proteins with RSBs.

Acknowledgment

This research was supported by the Doctoral Science Foundation of Liaoning University.

References

- Kashanian S, Gholivand MB, Ahmadia F, Taravati A and Colagar AH. DNA interaction with Al–N,N'bis (salicylidene) 2,2'-phenylendiamine complex. *Spectrochim. Acta A* (2007) 67: 472-478.
- (2) Patel NB and Patel VN. Synthesis and Antimicrobial Evaluation of w (4-Oxo-thiazolidinyl)quinazolin -4(3H)ones o[(2,6-Dichlorophenyl)amino] phenylacetic acid. *Iran. J. Pharm. Res.* (2007) 6: 251-258.
- (3) Huang GS, Liang YM, Wu XL, Liu WM and Ma YX. Some ferrocenyl Schiff bases with nonlinear optical properties. *Organomet. Chem.* (2003) 17: 706-710.
- (4) Curini M, Epifano F, Maltese F and Marcotullio MC. Amine-catalyzed direct Diels–Alder reactions of α,βunsaturated ketones with nitro olefins. *Tetrahedron Lett*. (2002) 43: 3821-3823.
- (5) Zhang LX, Liu Y, Cia LH, Hu YJ, Yin J and Hu PZ. Inhibitory study of some novel Schiff base derivatives on Staphylococcus aureus by microcalorimetry. *Thermochim. Acta.* (2006) 440: 51-56.
- (6) Keyser LA, Karl M, Nafziger AN and Bertino JJ. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med. (2000) 160: 1485-1488.
- (7) Demicheli V, Rivetti D, Deeks JJ and Jefferson TO. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst. Rev.* (2004) 3: 1-112.
- (8) Bulut H, Karatepe M, Temel H, Sekerci M and Koparir M. Synthesis and antibacterial activity of schiff bases derivative. *Asian J. Chem.* (2005) 17: 2793-2796.
- (9) Abdel-Latif SA, Hassib HB and Issa YM. Studies on some salicylaldehyde Schiff base derivatives and their complexes with Cr(III), Mn(II), Fe(III), Ni(II) and Cu(II). Spectrochimi. Acta Part A. (2007) 67: 950-957.
- (10) Beaudry F, Ross A, Lema PP and Vachon P. Pharmacokinetics of vanillin and its effects on mechanical hypersensitivity in a rat model of neuropathic pain. *Phytother. Res.* (2010) 24: 525-530.
- (11) Lim EJ, Kang HJ, Jung HJ, Song YS, Lim CJ and Park EH. Anti-angiogenic, anti-inflammatory and antinociceptive activities of vanillin in ICR mice. *Biomol.*

Ther: (2008) 16: 132-136.

- (12) Yazawa S, Okada M, Ono M, Fujii S, Okuda Y, Shibata I and Kida H. Experimental dual infection of pigs with an H1N1 swine influenza virus (A/Sw/Hok/2/81) and Mycoplasma hyopneumoniae. *Vet. Microbiol.* (2004) 98: 221-228.
- (13) Hirano T, Kurono Y, Ichimiya I, Suzuki M and Mogi G. Effects of influenza a virus on lectin-binding patterns in murine nasopharyngeal mucosa and on bacterial colonization. *Otolaryng. Head Neck Surg.* (1999) 121: 616-621.
- (14) Gómez-Gallego M, Mancheño MJ and Sierra MA. Non-Classical Polycyclic β-Lactams. *Tetrahedron*. (2000) 56: 5743-5774.
- (15) Stamler JS, Singel DJ and Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. *Sci.* (1992) 258: 1898-1902.
- (16) Shrivastava HY, Kanthimathi M and Niar BU. Interaction of Schiff Base with Bovine Serum Albumin: Site-Specific Photocleavage. *Biochem. Biophys. Res. Commun.* (1999) 265: 311-314.
- (17) Rawel HM, Frey SK, Meidtner K, Kroll J and Schweigert FJ. Determining the binding affinities of phenolic compounds to proteins by quenching of the intrinsic tryptophan fluorescence. *Mol. Nutr. Food Res.* (2006) 50: 705-713.
- (18) Lakowicz JR. "Principles of Fluorescence Spectroscopy". seconded, Plenum Press, New York (1999) 237-265.
- (19) Dewey TG. Biophysical and Biochemical Aspects of Fluorescence Spectroscopy. Plenum Press, New York (1991) 1-41.
- (20) Kandagal PB, Ashoka S, Seetharamappa J, Vani V and Shaikh SMT. Study of the interaction between doxepin and human serum albumin by spectroscopic methods. *J. Photochem. Photobiol. A* (2006) 179: 161-166.
- (21) Sudlow G, Birkett DJ and Wade DN. Further characterization of specific binding sites on human serum albumin. *Mol. Pharmacol.* (1976) 12: 1052-1061.
- (22) Bian HD, Li M and Qing Y. Study of the interaction of artemisinin with bovine serum albumin. *Int. J. Biol. Macromol.* (2006) 39: 291-297.

This article is available online at http://www.ijpr.ir